MO29-1 The relationship between EGFR variant allele frequency and efficacy of osimertinib in EGFR mutation-positive NSCLC

Abstract

The Oncomine Dx Target Test CDx system (oncomine) is used as an oncogene test for non-small cell carcinoma (NSCLC). Variant allele frequency (VAF) of oncogene is different in each epidermal growth factor receptor (EGFR) mutation-positive case. Association between VAF of EGFR and progression-free survival (PFS) of the first-generation EGFR-tyrosine kinase inhibitor (TKI) was reported previously. This retrospective study evaluated the relationship between VAF and the efficacy of Osimertinib as the first EGFR-TKI of each case.